The group will start a pivotal trial of samuraciclib following promising second-line results.

Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.

But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.

Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.

The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.

The ESMO presidential session will feature data from Destiny-Breast05 and 11.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.